These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
149 related items for PubMed ID: 2054795
1. Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Zugmaier G, Paik S, Wilding G, Knabbe C, Bano M, Lupu R, Deschauer B, Simpson S, Dickson RB, Lippman M. Cancer Res; 1991 Jul 01; 51(13):3590-4. PubMed ID: 2054795 [Abstract] [Full Text] [Related]
6. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Bandyopadhyay A, López-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, Sun LZ. Cancer Res; 2002 Aug 15; 62(16):4690-5. PubMed ID: 12183427 [Abstract] [Full Text] [Related]
7. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects. Tobin SW, Douville K, Benbow U, Brinckerhoff CE, Memoli VA, Arrick BA. Oncogene; 2002 Jan 03; 21(1):108-18. PubMed ID: 11791181 [Abstract] [Full Text] [Related]
8. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. Cancer Res; 1996 Apr 01; 56(7):1545-50. PubMed ID: 8603400 [Abstract] [Full Text] [Related]
9. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Bandyopadhyay A, Zhu Y, Cibull ML, Bao L, Chen C, Sun L. Cancer Res; 1999 Oct 01; 59(19):5041-6. PubMed ID: 10519421 [Abstract] [Full Text] [Related]
10. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M. Clin Cancer Res; 2001 Sep 01; 7(9):2931-40. PubMed ID: 11555612 [Abstract] [Full Text] [Related]
11. Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta. Arteaga CL, Coffey RJ, Dugger TC, McCutchen CM, Moses HL, Lyons RM. Cell Growth Differ; 1990 Aug 01; 1(8):367-74. PubMed ID: 2177634 [Abstract] [Full Text] [Related]
12. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines. Glinsky GV, Price JE, Glinsky VV, Mossine VV, Kiriakova G, Metcalf JB. Cancer Res; 1996 Dec 01; 56(23):5319-24. PubMed ID: 8968076 [Abstract] [Full Text] [Related]
13. Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Dickson RB, Bates SE, McManaway ME, Lippman ME. Cancer Res; 1986 Apr 01; 46(4 Pt 1):1707-13. PubMed ID: 2418952 [Abstract] [Full Text] [Related]
14. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA. Cell Growth Differ; 1993 Mar 01; 4(3):193-201. PubMed ID: 8466857 [Abstract] [Full Text] [Related]
15. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Moore LD, Isayeva T, Siegal GP, Ponnazhagan S. Clin Cancer Res; 2008 Aug 01; 14(15):4961-70. PubMed ID: 18676771 [Abstract] [Full Text] [Related]
16. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line. Yamamoto N, Imai J, Watanabe M, Hiroi N, Sugano S, Yoshino G. Horm Metab Res; 2006 Mar 01; 38(3):159-66. PubMed ID: 16673206 [Abstract] [Full Text] [Related]
17. Importance of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vivo. Kurachi H, Morishige K, Amemiya K, Adachi H, Hirota K, Miyake A, Tanizawa O. Cancer Res; 1991 Nov 01; 51(21):5956-9. PubMed ID: 1933859 [Abstract] [Full Text] [Related]
18. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P. Cancer Res; 2006 Feb 15; 66(4):2202-9. PubMed ID: 16489022 [Abstract] [Full Text] [Related]
19. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells. Ye SC, Foster JM, Li W, Liang J, Zborowska E, Venkateswarlu S, Gong J, Brattain MG, Willson JK. Cancer Res; 1999 Sep 15; 59(18):4725-31. PubMed ID: 10493532 [Abstract] [Full Text] [Related]
20. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments]. Dong AQ, Kong MJ, Ma ZY, Qian JF, Fan JQ, Xu XH. Zhonghua Yi Xue Za Zhi; 2007 Jun 05; 87(21):1506-9. PubMed ID: 17785094 [Abstract] [Full Text] [Related] Page: [Next] [New Search]